Evidence map›Paper›PMID 40685547›Full record

ArticleNucleic acids research2025

The dual ubiquitin binding mode of SPRTN secures rapid spatiotemporal proteolysis of DNA-protein crosslinks.

Wei Song, Yichen Zhao, Annamaria Ruggiano, Christina Redfield, Joseph A Newman, Xiaosheng Zhu, Marta García-Flores, Abimael Cruz-Migoni, Rebecca Roddan, Anna Pérez-Ràfols and 3 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Wei SongDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0002-2834-5671
Yichen ZhaoDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0009-0000-2820-4193
Annamaria RuggianoDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0003-4514-7922
Christina RedfieldDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.ORCID 0000-0001-7297-7708
Joseph A NewmanCentre for Medicines Discovery, University of Oxford, Oxford, OX3 7FZ, UK.ORCID 0000-0003-4488-0516
Xiaosheng ZhuDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.
Marta García-FloresCenter for Biological Research Margarita Salas (CIB-CSIC), Spanish National Research Council, Madrid, 28040, Spain.
Abimael Cruz-MigoniDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0001-5937-4101
Rebecca RoddanDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0002-9406-9011
Anna Pérez-RàfolsMRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.ORCID 0000-0001-7492-2583
Peter J McHughDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0002-8679-4627
Paul R ElliottDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.ORCID 0000-0002-7641-2103
Kristijan RamadanDepartment of Oncology, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.ORCID 0000-0001-5522-021X

Funding

Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI John A. Tainer · 2001 to 2026
$89.6M
Breast Cancer Now 2022.11PR1570Cancer Research UK A24759Cancer Research UK DRCRPG-Nov23/100005Cancer Research UK MR/X000192/1Edward Penley Abraham Cephalosporin FundEngineering and Physical Sciences Research Council EP/R029849/1John Fell FundLKC Medicine, SingaporeMedical Research Council MR/X006409/1Ministry of Education 023917-00001NCI NIH HHS P01 CA092584Spanish Ministry of Science, Innovation and UniversitiesState Research Agency RYC2022-036351-IToh Kian Chui Distinguished Professorship AwardUniversity of Oxford Wellcome Institutional Strategic Support FundWellcome Trust
6 · The paper itself

Abstract

DNA-protein crosslinks (DPCs) are endogenous and chemotherapy-induced genotoxic DNA lesions and, if not repaired, lead to embryonic lethality, neurodegeneration, premature ageing, and cancer. DPCs are heavily polyubiquitinated, and the SPRTN protease and 26S proteasome emerged as two central enzymes for DPC proteolysis. The proteasome recognizes its substrates by their ubiquitination status. How SPRTN protease, an essential enzyme for DPC proteolysis, achieves specificity for DPCs is still not entirely clear. We found that the N-terminal SPRTN catalytic region (SprT) possesses a ubiquitin-binding domain that we named the Ubiquitin Interface of SprT Domain (USD). Using multiple biochemical, biophysical, and structural approaches, we reveal that USD binds ubiquitin chains in an avidity manner. SPRTN binding to ubiquitin chains via USD leads to ∼67-fold higher activation of SPRTN proteolysis towards polyubiquitinated DPCs than the unmodified DPCs. In contrast, the constitutive components of the replisome during unperturbed or translesional DNA synthesis, namely proliferating cell nuclear antigen (PCNA) or monoUb-PCNA, respectively, were poorly degraded, if at all, by SPRTN. This study reveals that the poly-ubiquitination of DPCs serves as the key signal for SPRTN's rapid proteolysis and determines its substrate specificity towards DPCs, rather than the replisome.

Indexed as

DNADNA-Binding ProteinsUbiquitinCatalytic DomainDNA DamageDNA RepairHumansProliferating Cell Nuclear AntigenProteasome Endopeptidase ComplexProtein BindingProteolysisUbiquitinationATP dependent 26S proteaseDNADNA-Binding ProteinsProliferating Cell Nuclear AntigenProteasome Endopeptidase ComplexSPRTN protein, humanUbiquitin

Identifiers

PMID40685547
PMCPMC12277127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.